Therapeutic area intelligence for Hormonal Therapies with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Triastek →

Recent signals(1)

CompetitiveJune 30, 2026

Triastek Initiates Phase 1 Trial for Octreotide Acetate Tablets (T25) Bioavailability

Triastek is conducting Phase 1 trial to evaluate the bioavailability of T25 compared to Mycapssa and the food effect on pharmacokinetics.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.